Sagar Lonial, MD

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Sagar Lonial, MD, FACP, discusses unique subtypes of multiple myeloma identified through the CoMMpass study.

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

The panel debates the options for treatment of late relapsed multiple myeloma.

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

What to know in terms of dosing belantamab mafodotin treatment in patients with relapsed/refractory multiple myeloma.

Variables that impact treatment decisions for relapsed/refractory multiple myeloma.

Natalie Callander, MD, presents the profile of a female patient with relapsed/refractory multiple myeloma who receives belantamab mafodotin and develops keratopathy.

Karen L. Klugo, MD, describes what’s unique in terms of patient response to belantamab mafodotin as treatment for relapsed/refractory multiple myeloma and risk of ocular disease.

Sagar Lonial, MD, FACP, discusses the management of belantamab mafodotin-blmf–related keratopathy in patients with relapsed/refractory multiple myeloma.